In contrast, miR-106b-5p inhibitor (Figure 5(c)) and BTG3 overexpression (Figure 5(d)) had an opposite effect on G1/S-specific proteins and sorafenib resistance-related proteins in HCC-LM3 and MHCC-97H cells. This evidence concerns the gene BTG3 and hepatocellular carcinoma.